This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ranibizumab similar biologic launched in India. https://www.gabionline.net/biosimilars/news/Ranibizumab-similar-biologic-launched-in-India. Accessed July 23, 2022
Sharma A, Loewenstein A, Kuppermann BD. The future of biosimilar and biobetters in Ophthalmology. touchREVIEWS Ophthalmol. 2022;16:6–7.
Apsangikar P, Ghadge P, Naik M, Nair S, Payghan R. Randomised, double-blind, comparative clinical study of new ranibizumab biosimilar in neovascular (Wet) age-related macular degeneration. Clin Ophthalmol. 2021;15:3087–95.
Singh R, Chauhan R, Saxena A, Shah A, Mondal L, Bakhle D, et al. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin’s Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration. Indian J Ophthalmol. 2022;70:3008–14.
Sharma A, Kumar N, Bandello F, Loewenstein A, Kuppermann BD. Need of education on biosimilars amongst ophthalmologists: combating the nocebo effect. Eye. 2020;34:1006–7.
Acknowledgements
Dr Kuppermann acknowledges an unrestricted grant from Research to Prevent Blindness to the Gavin Herbert Eye Institute at the University of California, Irvine.
Author information
Authors and Affiliations
Contributions
AS: conception, analysis, drafting, integrity check, final approval NK, NP, FB, AL, BDK; drafting, revision, analysis, integrity check.
Corresponding author
Ethics declarations
Competing interests
Dr Ashish Sharma: CONSULTANT: for Novartis, Allergan, Bayer and Intas. Dr Francesco Bandello: CONSULTANT: Allergan, Bayer, Boehringer- Ingelheim, FidiaSooft, Hofmann La Roche, Novartis, NTC Pharma, Sifi, Thrombogenics, Zeiss. Dr Anat Loewenstein reports other from Allergan, other from Novartis, other from Roche, other from Notal Vision, other from Forsightslabs, other from Beyeonics, other from Bayer Health Care. Dr Baruch D Kuppermann: CLINICAL RESEARCH: Apellis, Genentech Inc, Boehringer Ingelheim, EyePoint, Ionis, IVERIC Bio, Novartis Pharmaceuticals, Regeneron Pharmaceuticals Inc, RegenXBio; CONSULTANT: Aviceda, Allegro Ophthalmics, Allergan/AbbVie, Bausch+Lomb, Boehringer Ingelheim, Clearside, Coherus, EyeBio, Eyedaptic, EyePoint, Genentech Inc, Glaukos Corporation, InflammX Therapeutics, IVERIC Bio, jCyte, Mobius, Neurotech Pharmaceuticals, Novartis Pharmaceuticals, Ocular Therapeutix, Outlook Therapeutics, Regeneron Pharmaceuticals Inc, ReVana Therapeutics, Ripple Therapeutics, Stealth Biotherapeutics, TechImmune, Theravance Biopharma, Visgenx. Dr Nilesh Kumar: None. Dr Nikulaa Parachuri: None.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Sharma, A., Kumar, N., Parachuri, N. et al. Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs. Eye (2024). https://doi.org/10.1038/s41433-024-03001-8
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41433-024-03001-8